Correction to: MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma

Detalles Bibliográficos
Autores principales: Xiong, Guangbing, Huang, Hua, Feng, Mengyu, Yang, Gang, Zheng, Suli, You, Lei, Zheng, Lianfang, Hu, Ya, Zhang, Taiping, Zhao, Yupei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Correction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8600783/
https://www.ncbi.nlm.nih.gov/pubmed/34794494
http://dx.doi.org/10.1186/s13046-021-02152-w
_version_ 1784601221925961728
author Xiong, Guangbing
Huang, Hua
Feng, Mengyu
Yang, Gang
Zheng, Suli
You, Lei
Zheng, Lianfang
Hu, Ya
Zhang, Taiping
Zhao, Yupei
author_facet Xiong, Guangbing
Huang, Hua
Feng, Mengyu
Yang, Gang
Zheng, Suli
You, Lei
Zheng, Lianfang
Hu, Ya
Zhang, Taiping
Zhao, Yupei
author_sort Xiong, Guangbing
collection PubMed
description
format Online
Article
Text
id pubmed-8600783
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-86007832021-11-19 Correction to: MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma Xiong, Guangbing Huang, Hua Feng, Mengyu Yang, Gang Zheng, Suli You, Lei Zheng, Lianfang Hu, Ya Zhang, Taiping Zhao, Yupei J Exp Clin Cancer Res Correction BioMed Central 2021-11-18 /pmc/articles/PMC8600783/ /pubmed/34794494 http://dx.doi.org/10.1186/s13046-021-02152-w Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Correction
Xiong, Guangbing
Huang, Hua
Feng, Mengyu
Yang, Gang
Zheng, Suli
You, Lei
Zheng, Lianfang
Hu, Ya
Zhang, Taiping
Zhao, Yupei
Correction to: MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma
title Correction to: MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma
title_full Correction to: MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma
title_fullStr Correction to: MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma
title_full_unstemmed Correction to: MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma
title_short Correction to: MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma
title_sort correction to: mir-10a-5p targets tfap2c to promote gemcitabine resistance in pancreatic ductal adenocarcinoma
topic Correction
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8600783/
https://www.ncbi.nlm.nih.gov/pubmed/34794494
http://dx.doi.org/10.1186/s13046-021-02152-w
work_keys_str_mv AT xiongguangbing correctiontomir10a5ptargetstfap2ctopromotegemcitabineresistanceinpancreaticductaladenocarcinoma
AT huanghua correctiontomir10a5ptargetstfap2ctopromotegemcitabineresistanceinpancreaticductaladenocarcinoma
AT fengmengyu correctiontomir10a5ptargetstfap2ctopromotegemcitabineresistanceinpancreaticductaladenocarcinoma
AT yanggang correctiontomir10a5ptargetstfap2ctopromotegemcitabineresistanceinpancreaticductaladenocarcinoma
AT zhengsuli correctiontomir10a5ptargetstfap2ctopromotegemcitabineresistanceinpancreaticductaladenocarcinoma
AT youlei correctiontomir10a5ptargetstfap2ctopromotegemcitabineresistanceinpancreaticductaladenocarcinoma
AT zhenglianfang correctiontomir10a5ptargetstfap2ctopromotegemcitabineresistanceinpancreaticductaladenocarcinoma
AT huya correctiontomir10a5ptargetstfap2ctopromotegemcitabineresistanceinpancreaticductaladenocarcinoma
AT zhangtaiping correctiontomir10a5ptargetstfap2ctopromotegemcitabineresistanceinpancreaticductaladenocarcinoma
AT zhaoyupei correctiontomir10a5ptargetstfap2ctopromotegemcitabineresistanceinpancreaticductaladenocarcinoma

Ejemplares similares